跳至主要内容
临床试验/ISRCTN12126820
ISRCTN12126820进行中(未招募)Unknown

Efficacy study of a food supplement based on Scutellaria lateriflora L. (aerial parts of the plant) for sleep management: single-center, controlled, randomized, cross-over, double-bind clinical study with a run-in period.

Epo S.r.l.0 个研究点目标入组 66 人开始时间: 2024年6月3日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1.Subjects aged 18 - 70 years of both sexes
  • 2.Subjects able to understand and sign the informed consent
  • 3.With primary insomnia, present for at least one month
  • 4.With ISI questionnaire scores <22
  • 5.With GAD-7 questionnaire scores <5
  • 6.With PHQ-9 questionnaire scores <5

排除标准

  • 1.Aged < 18 and > 70 years
  • 2.Pregnant or breastfeeding individuals
  • 3.Subjects with secondary insomnia or other sleep disorders, such as obstructive sleep apnea, narcolepsy, nocturnal myoclonus, restless legs syndrome, advanced sleep phase disorder, delayed sleep phase disorder, paradoxical insomnia, parasomnias
  • 4.Subjects with ISI questionnaire scores >22
  • 5.Subjects with GAD-7 questionnaire scores >5
  • 6.Subjects with PHQ-9 questionnaire scores >5
  • 7.Subjects suffering from psychiatric disorders: major depression, generalized anxiety disorder, post-traumatic stress disorder, panic attacks, bipolar disorder, dementia, schizophrenia
  • 8.Subjects with chronic and acute pain conditions (e.g., arthritis, fibromyalgia, back pain, headaches, respiratory diseases, asthma, diabetes, heart diseases, injuries, hyperthyroidism, gastroesophageal reflux, epilepsy, Parkinson's disease, Alzheimer's disease, kidney diseases)
  • 9.Subjects who abuse alcohol, amphetamines, caffeine, theine
  • 10.Subjects taking antidepressants, diuretics
  • 11.Subjects with hypothyroidism
  • 12.Subjects who have taken monoamine oxidase inhibitors in the 14 days prior to recruitment
  • 13.Subjects taking antibiotics or who have taken antibiotics in the last four weeks, or in the last 6 months, based on the intensity and duration of antibiotic treatment
  • 14.Subjects with cognitive disorders that may hinder the response to questionnaires
  • 15.Subjects with known allergy to the ingredients of the experimental products (active - placebo)
  • 16.Subjects with acquired immunodeficiency syndrome from HIV

研究者

发起方
Epo S.r.l.

相似试验